These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1096899)

  • 1. Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
    Bronaugh RL; MacMurtry RJ; Hoehn MM; Rutledge CO
    Biochem Pharmacol; 1975 Jul; 24(13-14):1317-20. PubMed ID: 1096899
    [No Abstract]   [Full Text] [Related]  

  • 2. Sulphate conjugation and L-dopa treatment of Parkinsonian patients.
    Rutledge CO; Hoehn MM
    Nature; 1973 Aug; 244(5416):447-50. PubMed ID: 4582501
    [No Abstract]   [Full Text] [Related]  

  • 3. MAO and L-dopa treatment of Parkinson's disease.
    Tyce GM; Dousa MK; Muenter MD
    J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
    Dutton J; Copeland LG; Playfer JR; Roberts NB
    Clin Chem; 1993 Apr; 39(4):629-34. PubMed ID: 8472357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
    Siirtola T; Sonninen V; Rinne UK
    Clin Neurol Neurosurg; 1975; 78(2):77-88. PubMed ID: 1222507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
    Bronaugh RL; Hattox SE; Hoehn MM; Murphy RC; Rutledge CO
    J Pharmacol Exp Ther; 1975 Dec; 195(3):441-52. PubMed ID: 1195131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 9. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine 3-O-sulphate, an end product of L-dopa metabolism in Parkinson patients.
    Jenner WN; Rose FA
    Nature; 1974 Nov; 252(5480):237-8. PubMed ID: 4422149
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
    Davidson DF; Grosset K; Grosset D
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
    Shoulson I; Glaubiger GA; Chase TN
    Neurology; 1975 Dec; 25(12):1144-8. PubMed ID: 812004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Parkinsonian syndrome and its dopamine correlates.
    Hoehn MM; Crowley TJ; Rutledge CO
    Adv Exp Med Biol; 1977; 90():243-54. PubMed ID: 930745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine correlates of neurological and psychological status in untreated Parkinsonism.
    Hoehn MM; Crowley TJ; Rutledge CO
    J Neurol Neurosurg Psychiatry; 1976 Oct; 39(10):941-51. PubMed ID: 1003240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation of levodopa metabolism with gastrointestinal absorption site.
    Sandler M; Ruthven CR; Goodwin BL; Hunter KR; Stern GM
    Lancet; 1974 Feb; 1(7851):238-40. PubMed ID: 4130247
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
    Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E
    Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
    Hardie RJ; Malcolm SL; Lees AJ; Stern GM; Allen JG
    Br J Clin Pharmacol; 1986 Oct; 22(4):429-36. PubMed ID: 3533125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic fate of levodopa in man and animals.
    Louis WJ; Doyle AE; Sampson RG
    Clin Exp Pharmacol Physiol; 1974; 1(4):341-6. PubMed ID: 4459002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.